Cypherpunk Technologies' Q3 net loss narrows

Reuters

Nov 12

Cypherpunk Technologies' Q3 net loss narrows

Overview

Cypherpunk Technologies reports Q3 net loss of $3.3 mln, down from $18.2 mln last year
Company acquires 203,775 ZEC for $50 mln as part of digital asset strategy
Closed $58.88 mln private placement led by Winklevoss Capital for digital asset strategy

Outlook

Company did not provide specific financial guidance for future quarters or year

Result Drivers

DIGITAL ASSET STRATEGY - Co established a digital asset treasury strategy focused on Zcash, acquiring over 203,775 ZEC for $50 mln
CLINICAL TRIAL RESULTS - Co presented final data from Phase 2 trial of sirexatamab in CRC patients, showing significant benefits
PRIVATE PLACEMENT - Co closed $58.88 mln private placement led by Winklevoss Capital to fund digital asset strategy

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$3.30 mln

Analyst Coverage

The one available analyst rating on the shares is "hold"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Press Release: ID:nPrezDBSka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582622371"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582622371\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582622371?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582622371","market":"us","top_or_hot":-1,"title":"Cypherpunk Technologies' Q3 net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cypherpunk Technologies' Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Cypherpunk Technologies reports Q3 net loss of $3.3 mln, down from $18.2 mln last year</p></li><li><p>Company acquires 203,775 ZEC for $50 mln as part of digital asset strategy</p></li><li><p>Closed $58.88 mln private placement led by Winklevoss Capital for digital asset strategy</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for future quarters or year</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>DIGITAL ASSET STRATEGY - Co established a digital asset treasury strategy focused on Zcash, acquiring over 203,775 ZEC for $50 mln</p></li><li><p>CLINICAL TRIAL RESULTS - Co presented final data from Phase 2 trial of sirexatamab in CRC patients, showing significant benefits</p></li><li><p>PRIVATE PLACEMENT - Co closed $58.88 mln private placement led by Winklevoss Capital to fund digital asset strategy</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.30 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nPrezDBSka</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cypherpunk Technologies' Q3 net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCypherpunk Technologies' Q3 net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 21:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cypherpunk Technologies' Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Cypherpunk Technologies reports Q3 net loss of $3.3 mln, down from $18.2 mln last year</p></li><li><p>Company acquires 203,775 ZEC for $50 mln as part of digital asset strategy</p></li><li><p>Closed $58.88 mln private placement led by Winklevoss Capital for digital asset strategy</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for future quarters or year</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>DIGITAL ASSET STRATEGY - Co established a digital asset treasury strategy focused on Zcash, acquiring over 203,775 ZEC for $50 mln</p></li><li><p>CLINICAL TRIAL RESULTS - Co presented final data from Phase 2 trial of sirexatamab in CRC patients, showing significant benefits</p></li><li><p>PRIVATE PLACEMENT - Co closed $58.88 mln private placement led by Winklevoss Capital to fund digital asset strategy</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.30 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nPrezDBSka</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYPH","symbol_name":"Cypherpunk Technologies Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0GD:1","article_id":"2582622371","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582622371","pubTimestamp":1762953220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cypherpunk Technologies' Q3 net loss narrowsOverviewCypherpunk Technologies reports Q3 net loss of $3.3 mln, down from $18.2 mln last yearCompany acquires 203,775 ZEC for $50 mln as part of digital as","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CYPH":"Cypherpunk Technologies Inc.","LPTX":"Leap Therapeutics Inc","BK4505":"高瓴资本持仓","BK4563":"昨日强势股","BK4139":"生物科技"},"translate_title":"Cypherpunk Technologies第三季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYPH":0.9,"LPTX":0.9},"content_text":"Cypherpunk Technologies' Q3 net loss narrowsOverviewCypherpunk Technologies reports Q3 net loss of $3.3 mln, down from $18.2 mln last yearCompany acquires 203,775 ZEC for $50 mln as part of digital asset strategyClosed $58.88 mln private placement led by Winklevoss Capital for digital asset strategyOutlookCompany did not provide specific financial guidance for future quarters or yearResult DriversDIGITAL ASSET STRATEGY - Co established a digital asset treasury strategy focused on Zcash, acquiring over 203,775 ZEC for $50 mlnCLINICAL TRIAL RESULTS - Co presented final data from Phase 2 trial of sirexatamab in CRC patients, showing significant benefitsPRIVATE PLACEMENT - Co closed $58.88 mln private placement led by Winklevoss Capital to fund digital asset strategyKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$3.30 mlnAnalyst CoverageThe one available analyst rating on the shares is \"hold\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Press Release: ID:nPrezDBSkaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}